Annals of Gastroenterological Surgery (Sep 2022)

Liver transplantation for intrahepatic and hilar cholangiocellular carcinoma: Most recent updates in the literature

  • Susumu Eguchi,
  • Masaaki Hidaka,
  • Takanobu Hara,
  • Hajime Matsushima,
  • Akihiko Soyama

DOI
https://doi.org/10.1002/ags3.12567
Journal volume & issue
Vol. 6, no. 5
pp. 616 – 622

Abstract

Read online

Abstract Liver transplantation (LT) for non‐hepatocellular carcinoma is still a debatable indication. Recently, hilar cholangiocellular carcinoma (hCCC) has attracted interest as a new indication for LT, but LT in this case should be carefully considered. Based on the recent meta‐analysis for intrahepatic CCC (IHCCC) and our results from incidental IHCCC transplanted for other diseases such as primary sclerosing cholangitis, the indication for LT for IHCCC should be limited to a single tumor less than 2 cm. For hCCC, with pre‐transplant chemoradiotherapy and careful selection criteria, long‐term survival after LT could be attained. In order to improve the results of LT for intrahepatic and hCCC, further studies are required on the ingenuity of immunosuppressive therapy combined with chemotherapy, and optimal treatment methods to prevent recurrence, as well as initial case selection.

Keywords